Abstract

Acute graft-vs.-host disease (aGvHD) is one of the most frequent causes of transplant-related mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). Its treatment is complex and costly. The aim of this study was to retrospectively analyze the impact of country-specific socioeconomic factors on outcome of patients who experience severe aGvHD. Adults with hematological malignancies receiving alloHCT from either HLA-matched siblings (n = 1,328) or unrelated donors (n = 2,824) developing grade 3 or 4 aGvHD were included. In univariate analysis, the probability of TRM at 2 years was increased for countries with lower current Health Care Expenditure (HCE, p = 0.04), lower HCE as % of Gross Domestic Product per capita (p = 0.003) and lower values of the Human Development Index (p = 0.02). In a multivariate model, the risk of TRM was most strongly predicted by current HCE (HR = 0.76, p = 0.006). HCE >median was also associated with reduced risk of the overall mortality (HR 0.73, p = 0.0006) and reduced risk of treatment failure (either relapse or TRM; HR 0.77, p = 0.004). We conclude that country-specific socioeconomic factors, in particular current HCE, are strongly associated with survival of patients who experience severe aGvHD.

Highlights

  • Allogeneic hematopoietic cell transplantation is widely used for the treatment of hematological malignancies

  • In the current study we analyzed a large cohort of patients who experienced severe Acute graft-vs.-host disease (aGvHD) after Allogeneic hematopoietic cell transplantation (alloHCT) from either MSD or unrelated donor (URD)

  • Based on the European Society for Blood and Marrow Transplantation (EBMT) registry, including 4,152 individuals, we clearly demonstrated that these factors are associated with transplant-related mortality (TRM), progressionfree survival (PFS) and Overall survival (OS)

Read more

Summary

Introduction

Allogeneic hematopoietic cell transplantation (alloHCT) is widely used for the treatment of hematological malignancies. Acute graft-vs.-host disease (aGvHD) is one of the most frequent complications of alloHCT. Initial treatment of aGvHD is well established. It consists of high doses of glucocorticosteroids and is effective in approximately two thirds of the patients [4]. Treatment of steroid-refractory aGvHD is not well standardized and is associated with dismal prognosis [5]. It must be accompanied by intensive supportive care to treat secondary complications, in particular infections associated with profound immunosuppression. The therapy of severe aGvHD is complex and costly. It requires experience, and resources and appropriate settings

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call